Ligand Pharma (LGND) Misses Q1 EPS by 21c
Tweet
Share
E-mailGet Alerts LGND Hot Sheet
Price: $285.95 -1.31%
Revenue Growth %: -32.2%
Financial Fact:
Decrease (increase) in liability for contingent value rights: -958K
Today's EPS Names:
PMCB, CULP, HURC, More
Revenue Growth %: -32.2%
Financial Fact:
Decrease (increase) in liability for contingent value rights: -958K
Today's EPS Names:
PMCB, CULP, HURC, More
Join SI Premium – FREE
Ligand Pharma (NASDAQ: LGND) reported Q1 EPS of $1.63, $0.21 worse than the analyst estimate of $1.84. Revenue for the quarter came in at $51.72 million versus the consensus estimate of $59.07 million.
For earnings history and earnings-related data on Ligand Pharma (LGND) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Dell’s earning report was bullish for Intel CPU demand, analyst says
- SK Hynix (SKHY) call put ratio 1.4 calls to 1 put as share price up 3.8%
- Western Digital (WDC) call put ratio 1.1 calls to 1 put as share price up 4.2%
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
